Delta Capita has launched its new technology platform, Elaris OTC, in a bid to enhance post-trade processes for OTC derivatives.
The solution, which is powered by blockchain platform operator, Fragmos Chain, is set to reduce operational costs and risk by allowing OTC derivatives trades and lifecycle events to be automatically matched between market participants.
The offering will also translate native client messaging formats into the common domain model (CDM) standard, to drive interoperability.
Mark Aldous, global head of capital markets managed services at Delta Capita, said: “This end-to-end offering brings together best-in-class technology and proven operational capabilities. Fully digital, CDM-aligned, and scalable, Elaris OTC sets a new standard for the industry.”
Additionally, the platform can also be combined with Delta Capita’s global OTC confirmation and settlement services, to allow all users beyond just platform participants to capture and manage interactions with counterparties, regardless of if they use the platform or not.
“By integrating with Delta Capita’s services, Elaris OTC delivers immediate impact and accelerates adoption for both sell-side and buy-side firms,” said Daniel Ivanier, chief executive of Fragmos Chain.
The firm has said that the development of the solution was driven by the need for a fully digitised solution, and pointed to inefficiencies and fragmentation in the OTC derivatives market, stating that approximately 20% of trades are still confirmed and settled manually.
The offering follows the firm’s multi-year agreement with HSBC established in January 2025, which sees Delta Capita delivering OTC derivatives confirmation and settlement services globally.
The firm has also seen further developments in recent months, including the acquisition of LSEG’s CLM technology, as well as the launch of its MACH Distributed Ledger product suite, which offers capital markets blockchain software.